Amgen NASDAQ: AMGN pharmaceutical company just released a report stating outstanding performance results for Pivotal Postmenopausal Osteoporosis Trial for denosumab.

Trial met primary endpoint of Reducing new vertebral fractures and secondary endpoints of decreasing time to first non-vertebral and hip fractures; adverse events similar to placebo. The immediate past president of the National Osteoporosis Foundation was excited." I am particularly excited about these findings because they indicate that denosumab may offer an important new option for patients."

Denosumab is the first fully human monoclonal antibody in late stage clinical development that specifically targets RANK Ligand, an essential regulator of osteoclasts (these are the cells that break the bone down). Denosumab is being investigated for its ability to inhibit every stage of osteoclast activity by a targeted mechanism. Denosumab is being researched in a range of bone loss illnesses including rheumatoid arthritis, postmenopausal osteoporosis, and cancer treatment-induced bone loss in breast cancer and prostate cancer patients| in prostate cancer and breast cancer patients as well as for its potential to delay bone metastases and stop and treat bone destruction for many stages of cancer.

Osteoporosis is often referred to as the "silent epidemic", osteoporosis is a global problem illness that is growing in dominance as the population of the world both ages and increases. The World Health Organization (WHO) has just claimed osteoporosis as a significant health issue along with other major non-communicable diseases. We are dependent on the pharmaceutical industry to help combat this terrible disease.

According to Amgen the financial burden of osteoporosis is comparable to as the "silent epidemi' to that of other major chronic diseases; for example, in the U.S. the costs associated with osteoporosis-related fractures are equivalent to those of cardiovascular disease and asthma (i)(ii)(iii). It has been reported that osteoporosis results in more hospital bed-days than stroke, myocardial infarction or breast cancer (iv).

Pharmacist-clinical have been researching prescriptions drugs to help patient who experience serious side effects. These products are created almost at the same time as the medications that aid in the treatment of the initial illness. The fact that research is available to help anticipate the potential side effects and interactions drugs have with one another is awesome.

These medicines are prescribed to prevent and treat osteoporosis. A few prescriptions increase bone thickness or slow the rate of bone loss. Even small amounts of new bone growth may diminish the danger of broken bones. It is essential that you take vitamin D and calcium, exercise and eat well when you take osteoporosis prescriptions.

prescription drug